Researchers at Mount Sinai Hospital and Yale University say they are the first to identify express blood biomarkers that can, as they should, identify long Covid, allowing them to create a set of rules for determining whether a patient has a persistent condition, according to a new study published Monday in the journal Nature.
The study shows that patients with long Covid have obvious immune and hormonal differences with respect to patients who do not suffer from the disease.
The researchers analyzed 271 at Mount Sinai Hospital, Mount Sinai Union Square and Yale School of Medicine between January 2021 and June 2022.
After dividing them into 3 teams, they were answered a questionnaire: those who had never had Covid-19, those who had fully recovered from a shown case of the virus, and those who had active symptoms of long Covid at least 4 months after having had Covid. -19 – were able to analyze similarities and differences in a number of biomarkers to create a set of rules for which patients belonged to which group.
According to the study, this set of rules makes it possible to know which patients had long Covid with 96% accuracy.
The researchers said the biggest thing they discovered in long-term Covid patients was the extent of immune and hormonal dysfunction.
They said the peak vital points were T-mobile activity (which refers to the ability of mobiles to activate the immune system), reactivation of various latent viruses (or the ability of the immune system to provoke its reaction to express viruses), and discounts on cortisol. . levels (which regulates, among other things, your body’s tension levels).
How this can be implemented in the real world. The study’s lead researcher, David Putrino, who works with the Icahn Mount Sinai School of Medicine, said the study’s findings “may indicate more delicate tests for long COVID patients” and be used to create “personalized remedies for long COVID that, so far, have not demonstrated clinical justification. Overall, Putrino said the study provides clinical validity to reports from long Covid patients, though he notes that doctors want to pay attention to patients and come up with personalized treatment plans.
“There is no ‘silver bullet’ to treat long COVID, as it is a disease that infiltrates systems such as immune and hormonal regulation,” Putrino said.
Long Covid is an illness that occurs when patients continue to experience symptoms and sequelae of Covid-19, such as brain fog or difficulty exercising, long after the initial infection. It first became known in the spring of 2020 through online lay patient groups, and eventually, the mainstream medical network took notice. Doctors still know very little about long Covid, but this study marks a significant advance in understanding the disease.
One in 13, or 7. 5%. That’s the proportion of the entire U. S. adult population. A number of U. S. people who had long Covid symptoms in June, whether they were inflamed or not, according to the Centers for Disease Control and Prevention, which explained long Covid as symptoms lasting at least 3 months after a first infection. Among patients who have had Covid-19 in the past, this number is one in five.
The study comes as fitness experts fear a possible new wave of the virus this fall. In the week ending Sept. 9, the maximum recent data available, 20,538 people in the U. S. were killed. The number of U. S. hospitalizations with Covid-19, according to the CDC, represents a 7. 7% increase from last week, still a far cry from the peak in January 2022, when there were about 150,000 hospitalizations. Since the start of the pandemic, 1. 14 million people in the U. S. have been living in the U. S. Some U. S. people have died from the virus.
People with long COVID have different hormonal and immune differences than those without the disease (Nature)
NIH Opens Clinical Trials for Long Covid Treatments (Forbes)
The anti-covid drug Paxlovid is now less effective than in early trials, but it’s still wonderful at preventing death (Forbes)
Full policy and updates on the coronavirus.